{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T12:02:55Z","timestamp":1784894575621,"version":"3.55.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100005258","name":"National Center for HIV\/AIDS, Viral Hepatitis, STD, and TB Prevention","doi-asserted-by":"publisher","award":["5U01PS005259"],"award-info":[{"award-number":["5U01PS005259"]}],"id":[{"id":"10.13039\/100005258","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Behav"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s10461-026-05039-z","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T07:48:39Z","timestamp":1769586519000},"page":"2140-2155","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Facilitators and Barriers to Home-Based Long-Acting Injectable Antiretroviral Therapy: Clinician Perspectives from the INVITE-Home Study"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0268-9277","authenticated-orcid":false,"given":"Alicia T.","family":"Bolton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Bourdeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"O\u2019Shea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Rebchook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Van Nuys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orlando O.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mallory O.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Starley B.","family":"Shade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Palomares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Buchacz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parya","family":"Saberi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"issue":"5","key":"5039_CR1","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1080\/17512433.2018.1453805","volume":"11","author":"L Benitez-Gutierrez","year":"2018","unstructured":"Benitez-Gutierrez L, Soriano V, Requena S, Arias A, Barreiro P, de Mendoza C. Treatment and prevention of HIV infection with long-acting antiretrovirals. Expert Rev Clin Pharmacol. 2018;11(5):507\u201317. https:\/\/doi.org\/10.1080\/17512433.2018.1453805.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"9","key":"5039_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26006","volume":"25","author":"CP Garris","year":"2022","unstructured":"Garris CP, Czarnogorski M, Dalessandro M, et al. Perspectives of people living with HIV-1 on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation-effectiveness study. J Int AIDS Soc. 2022;25(9):e26006. https:\/\/doi.org\/10.1002\/jia2.26006.","journal-title":"J Int AIDS Soc"},{"key":"5039_CR3","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1002\/jia2.26099","volume":"26","author":"SM Graham","year":"2023","unstructured":"Graham SM, Barthold D, Hauber B, et al. U.S. Patient preferences for long-acting HIV treatment: a discrete choice experiment. J Int AIDS Soc. 2023;26:1758\u20132652.","journal-title":"J Int AIDS Soc"},{"issue":"12","key":"5039_CR4","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","volume":"382","author":"S Swindells","year":"2020","unstructured":"Swindells S, Andrade-Villanueva JF, Richmond GJ, et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N Engl J Med. 2020;382(12):1112\u201323. https:\/\/doi.org\/10.1056\/NEJMoa1904398.","journal-title":"N Engl J Med"},{"issue":"3","key":"5039_CR5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/Qai.0000000000002337","volume":"84","author":"MM Philbin","year":"2020","unstructured":"Philbin MM, Parish CL, Kinnard EN, et al. Multisite study of women living with HIV\u2019s perceived barriers to, and interest in, long-acting injectable antiretroviral therapy. JAIDS J Acquir Immune Defic Syndr. 2020;84(3):263\u201370. https:\/\/doi.org\/10.1097\/Qai.0000000000002337.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"issue":"12","key":"5039_CR6","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMoa1909512","volume":"382","author":"C Orkin","year":"2020","unstructured":"Orkin C, Arasteh K, Hernandez-Mora MG, et al. Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection. N Engl J Med. 2020;382(12):1124\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1909512.","journal-title":"N Engl J Med"},{"issue":"10267","key":"5039_CR7","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1016\/S0140-6736(20)32666-0","volume":"396","author":"ET Overton","year":"2021","unstructured":"Overton ET, Richmond G, Rizzardini G, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet. 2021;396(10267):1994\u20132005. https:\/\/doi.org\/10.1016\/S0140-6736(20)32666-0.","journal-title":"Lancet"},{"issue":"4","key":"5039_CR8","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1097\/Qai.0000000000002466","volume":"85","author":"G Rizzardini","year":"2020","unstructured":"Rizzardini G, Overton ET, Orkin C, et al. Long-acting injectable cabotegravir plus rilpivirine for HIV maintenance therapy: week 48 pooled analysis of phase 3 ATLAS and FLAIR trials. JAIDS-J Acq Imm Def Syn. 2020;85(4):498\u2013506. https:\/\/doi.org\/10.1097\/Qai.0000000000002466.","journal-title":"JAIDS-J Acq Imm Def Syn"},{"key":"5039_CR9","unstructured":"Czarnogorski M, Garris C, D\u2019Amico R et al. CUSTOMIZE: overall results from a hybrid III implementation-effectiveness study examining implementation of cabotegravir and rilpivirine long-acting injectable for HIV treatment in US healthcare settings; final patient and provider data (Abstract OAD0705). 2021."},{"issue":"1","key":"5039_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26282","volume":"27","author":"N Nguyen","year":"2024","unstructured":"Nguyen N, Lane B, Golub SA, et al. Long-acting injectable ART to advance health equity: a descriptive analysis of US clinic perspectives on barriers, needed support and programme goals for implementation from applications to the ALAI UP project. J Int AIDS Soc. 2024;27(1):e26282. https:\/\/doi.org\/10.1002\/jia2.26282.","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"5039_CR11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/Qco.0000000000000701","volume":"34","author":"J Thornhill","year":"2021","unstructured":"Thornhill J, Orkin C. Long-acting injectable HIV therapies: the next frontier. Curr Opin Infect Dis. 2021;34(1):8\u201315. https:\/\/doi.org\/10.1097\/Qco.0000000000000701.","journal-title":"Curr Opin Infect Dis"},{"key":"5039_CR12","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac631","author":"KA Christopoulos","year":"2022","unstructured":"Christopoulos KA, Grochowski J, Mayorga-Munoz F, et al. First Demonstration Project of Long-Acting Injectable Antiretroviral Therapy for Persons With and Without Detectable Human Immunodeficiency Virus (HIV) Viremia in an Urban HIV Clinic. Clin Infect Dis. 2022. https:\/\/doi.org\/10.1093\/cid\/ciac631.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"5039_CR13","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/jmwh.13190","volume":"66","author":"M Marx","year":"2021","unstructured":"Marx M. Evidence-based guidance for self-administration of injectable contraception. J Midwifery Womens Health. 2021;66(1):108\u201312. https:\/\/doi.org\/10.1111\/jmwh.13190.","journal-title":"J Midwifery Womens Health"},{"key":"5039_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fgwh.2022.890017","volume":"3","author":"C Morozoff","year":"2022","unstructured":"Morozoff C, Cover J, Namagembe A, et al. Contraceptive self-injection through routine service delivery: health worker perspectives from Uganda. Front Glob Womens Health. 2022;3:890017. https:\/\/doi.org\/10.3389\/fgwh.2022.890017.","journal-title":"Front Glob Womens Health"},{"key":"5039_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-018-6015-3","author":"DB Cohen","year":"2018","unstructured":"Cohen DB, Phiri M, Banda H, Squire SB, Namakhoma I, Desmond N. A qualitative evaluation of hospital versus community-based management of patients on injectable treatments for tuberculosis. BMC Public Health. 2018. https:\/\/doi.org\/10.1186\/s12889-018-6015-3.","journal-title":"BMC Public Health"},{"issue":"1","key":"5039_CR16","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1136\/thoraxjnl-2018-212675","volume":"75","author":"DB Cohen","year":"2020","unstructured":"Cohen DB, Mbendera K, Maheswaran H, et al. Delivery of long-term-injectable agents for TB by lay carers: pragmatic randomised trial. Thorax. 2020;75(1):64\u201371. https:\/\/doi.org\/10.1136\/thoraxjnl-2018-212675.","journal-title":"Thorax"},{"key":"5039_CR17","unstructured":"Dieterich M, Patel R, Gouzoulis M et al. Home CAB\/RPV provides novel approach to achieve viral suppression in PWH with adherence challenges. 2025."},{"issue":"2","key":"5039_CR18","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1080\/15267431.2011.561140","volume":"12","author":"B Bourdeau","year":"2012","unstructured":"Bourdeau B, Miller B, Vanya M, Duke M, Ames G. Defining alcohol-specific rules among parents of older adolescents: moving beyond no tolerance. J Fam Commun. 2012;12(2):111\u201328. https:\/\/doi.org\/10.1080\/15267431.2011.561140.","journal-title":"J Fam Commun"},{"issue":"2","key":"5039_CR19","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1097\/QAI.0000000000003128","volume":"92","author":"P Saberi","year":"2023","unstructured":"Saberi P, Stoner MCD, Eskaf S, et al. Preferences for HIV treatment formulations among young adults with HIV in the United States. JAIDS J Acquir Immune Defic Syndr. 2023;92(2):e7\u201310. https:\/\/doi.org\/10.1097\/QAI.0000000000003128.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"issue":"2","key":"5039_CR20","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1097\/Qai.0000000000001896","volume":"80","author":"ED Weld","year":"2019","unstructured":"Weld ED, Rana MS, Dallas RH, et al. Interest of youth living with HIV in long-acting antiretrovirals. JAIDS J Acquir Immune Defic Syndr. 2019;80(2):190\u20137. https:\/\/doi.org\/10.1097\/Qai.0000000000001896.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"key":"5039_CR21","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000003661","author":"JI Gutierrez","year":"2025","unstructured":"Gutierrez JI, Montgomery ET, Dilworth SE, et al. Identifying preferred program delivery attributes for long-acting injectable cabotegravir-rilpivirine in three U.S. HIV clinics: a discrete choice experiment. JAIDS J Acquir Immune Defic Syndr. 2025. https:\/\/doi.org\/10.1097\/QAI.0000000000003661.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"key":"5039_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae472","author":"SE Kirk","year":"2024","unstructured":"Kirk SE, Young C, Berry H, et al. Comparison of at-home versus in-clinic receipt of long-acting injectable cabotegravir\/rilpivirine. Clin Infect Dis. 2024. https:\/\/doi.org\/10.1093\/cid\/ciae472.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"5039_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae265","volume":"11","author":"LF Collins","year":"2024","unstructured":"Collins LF, Koester KA, McNulty MC, et al. Patient attitudes toward self- or partner-, friend-, or family-administered long-acting injectable antiretroviral therapy: a mixed-methods study across 3 urban human immunodeficiency virus clinics. Open Forum Infect Dis. 2024;11(6):ofae265. https:\/\/doi.org\/10.1093\/ofid\/ofae265.","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"5039_CR24","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1080\/09540121.2020.1764906","volume":"33","author":"D Dandachi","year":"2021","unstructured":"Dandachi D, Dang BN, Lucari B, Swindells S, Giordano TP. Acceptability and preferences for long-acting antiretroviral formulations among people with HIV infection. AIDS Care. 2021;33(6):801\u20139. https:\/\/doi.org\/10.1080\/09540121.2020.1764906.","journal-title":"AIDS Care"},{"issue":"12","key":"5039_CR25","doi-asserted-by":"publisher","first-page":"4180","DOI":"10.1007\/s10461-021-03357-y","volume":"25","author":"CT Rael","year":"2021","unstructured":"Rael CT, Lopez-Rios J, McKenna SA, et al. Transgender women\u2019s barriers, facilitators, and preferences on tailored injection delivery strategies to administer long-acting injectable cabotegravir (CAB-LA) for HIV pre-exposure prophylaxis (PrEP). AIDS Behav. 2021;25(12):4180\u201392. https:\/\/doi.org\/10.1007\/s10461-021-03357-y.","journal-title":"AIDS Behav"},{"issue":"5","key":"5039_CR26","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1007\/s10461-019-02703-5","volume":"24","author":"CT Rael","year":"2020","unstructured":"Rael CT, Martinez M, Giguere R, et al. Transgender women\u2019s concerns and preferences on potential future long-acting biomedical HIV prevention strategies: the case of injections and implanted medication delivery devices (IMDDs). AIDS Behav. 2020;24(5):1452\u201362. https:\/\/doi.org\/10.1007\/s10461-019-02703-5.","journal-title":"AIDS Behav"},{"key":"5039_CR27","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1007\/s40271-023-00641-y","volume":"16","author":"M Emmert","year":"2023","unstructured":"Emmert M, Rohrbacher S, Jahn J, Fernando K, Lauerer M. Preferences of people living with HIV for long-acting antiretroviral treatment in Germany: evidence from a discrete choice experiment. Patient. 2023;16:1178\u2013661.","journal-title":"Patient"},{"issue":"1","key":"5039_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s13012-020-01041-8","volume":"15","author":"JD Smith","year":"2020","unstructured":"Smith JD, Li DH, Rafferty MR. The implementation research logic model: a method for planning, executing, reporting, and synthesizing implementation projects. Implement Sci. 2020;15(1):84. https:\/\/doi.org\/10.1186\/s13012-020-01041-8.","journal-title":"Implement Sci"},{"key":"5039_CR29","doi-asserted-by":"publisher","DOI":"10.1177\/1609406920937875","volume":"19","author":"B Lobe","year":"2020","unstructured":"Lobe B, Morgan D, Hoffman KA. Qualitative data collection in an era of social distancing. Int J Qual Methods. 2020;19:1609406920937875. https:\/\/doi.org\/10.1177\/1609406920937875.","journal-title":"Int J Qual Methods"},{"key":"5039_CR30","unstructured":"Cloud application for managing, analyzing, and presenting qualitative and mixed method research data. SocioCultural Research Consultants, LLC; 2023. Accessed Accessed September 15, 2025. https:\/\/dedoose.com"},{"key":"5039_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/1748-5908-4-50","volume":"4","author":"LJ Damschroder","year":"2009","unstructured":"Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009;4:50. https:\/\/doi.org\/10.1186\/1748-5908-4-50.","journal-title":"Implement Sci"},{"issue":"1","key":"5039_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s13012-022-01245-0","volume":"17","author":"LJ Damschroder","year":"2022","unstructured":"Damschroder LJ, Reardon CM, Widerquist MAO, Lowery J. The updated consolidated framework for implementation research based on user feedback. Implement Sci. 2022;17(1):75. https:\/\/doi.org\/10.1186\/s13012-022-01245-0.","journal-title":"Implement Sci"},{"issue":"2","key":"5039_CR33","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10488-010-0319-7","volume":"38","author":"E Proctor","year":"2011","unstructured":"Proctor E, Silmere H, Raghavan R, et al. Outcomes for implementation research: conceptual distinctions, measurement challenges, and research agenda. Adm Policy Ment Health. 2011;38(2):65\u201376. https:\/\/doi.org\/10.1007\/s10488-010-0319-7.","journal-title":"Adm Policy Ment Health"},{"issue":"4","key":"5039_CR34","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1097\/QAI.0000000000003370","volume":"95","author":"S Keddem","year":"2024","unstructured":"Keddem S, Thatipelli S, Caceres O, Roder N, Momplaisir F, Cronholm P. Barriers and facilitators to long-acting injectable HIV pre-exposure prophylaxis implementation in primary care since its approval in the United States. JAIDS J Acquir Immune Defic Syndr. 2024;95(4):370\u20136. https:\/\/doi.org\/10.1097\/QAI.0000000000003370.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"issue":"3","key":"5039_CR35","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1037\/0022-006x.49.3.418","volume":"49","author":"A Rosen","year":"1981","unstructured":"Rosen A, Proctor EK. Distinctions between treatment outcomes and their implications for treatment evaluation. J Consult Clin Psychol. 1981;49(3):418\u201325. https:\/\/doi.org\/10.1037\/0022-006x.49.3.418.","journal-title":"J Consult Clin Psychol"},{"issue":"3","key":"5039_CR36","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1089\/apc.2023.0250","volume":"38","author":"NM Nguyen","year":"2024","unstructured":"Nguyen NM, Kavanagh R, Gozar M, et al. Implementation of a pharmacist-led, long-acting, injectable cabotegravir\/rilpivirine program for HIV-1 at health system-based clinics in the New York Metropolitan Area. AIDS Patient Care STDS. 2024;38(3):115\u201322. https:\/\/doi.org\/10.1089\/apc.2023.0250.","journal-title":"AIDS Patient Care STDS"},{"issue":"1","key":"5039_CR37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/coh.0000000000000904","volume":"20","author":"KA Christopoulos","year":"2025","unstructured":"Christopoulos KA, Hickey MD, Rana A. Use of long-acting injectable cabotegravir\/rilpivirine in people with HIV and adherence challenges. Curr Opin HIV AIDS. 2025;20(1):11\u20138. https:\/\/doi.org\/10.1097\/coh.0000000000000904.","journal-title":"Curr Opin HIV AIDS"},{"key":"5039_CR38","doi-asserted-by":"publisher","unstructured":"Gutierrez JI Jr., Montgomery ET, Dilworth SE, et al. Identifying preferred program delivery attributes for long-acting injectable cabotegravir-rilpvirine in three U.S. HIV clinics: a discrete choice experiment. J Acquir Immune Defic Syndr. 2025;99(3):248\u201357. https:\/\/doi.org\/10.1097\/QAI.0000000000003661.","DOI":"10.1097\/QAI.0000000000003661"},{"issue":"7","key":"5039_CR39","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac293","volume":"9","author":"KA Christopoulos","year":"2022","unstructured":"Christopoulos KA, Colasanti J, Johnson MO, et al. Are patients and their providers talking about long-acting injectable antiretroviral therapy? Penetration into clinical encounters at three U.S. care sites. Open Forum Infect Dis. 2022;9(7):ofac293. https:\/\/doi.org\/10.1093\/ofid\/ofac293.","journal-title":"Open Forum Infect Dis"},{"issue":"9","key":"5039_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26003","volume":"25","author":"M Czarnogorski","year":"2022","unstructured":"Czarnogorski M, Garris CP, Dalessandro M, et al. Perspectives of healthcare providers on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings from a Hybrid III implementation-effectiveness study (CUSTOMIZE). J Int AIDS Soc. 2022;25(9):e26003. https:\/\/doi.org\/10.1002\/jia2.26003.","journal-title":"J Int AIDS Soc"},{"issue":"12","key":"5039_CR41","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1089\/AID.2024.0007","volume":"40","author":"GC Haser","year":"2024","unstructured":"Haser GC, Balter L, Gurley S, et al. Early implementation and outcomes among people with HIV who accessed long-acting injectable cabotegravir\/rilpivirine at two Ryan White clinics in the U.S. South. AIDS Res Hum Retroviruses. 2024;40(12):690\u2013700. https:\/\/doi.org\/10.1089\/AID.2024.0007.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"3","key":"5039_CR42","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1097\/QAI.0000000000003421","volume":"96","author":"MD Hickey","year":"2024","unstructured":"Hickey MD, Grochowski J, Mayorga-Munoz F, et al. Identifying implementation determinants and strategies for long-acting injectable Cabotegravir-Rilpivirine in people with HIV who are virally unsuppressed. J Acquir Immune Defic Syndr. 2024;96(3):280\u20139. https:\/\/doi.org\/10.1097\/QAI.0000000000003421.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"5039_CR43","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/hiv.13701","volume":"26","author":"HZ Farooq","year":"2025","unstructured":"Farooq HZ, Whitton L, Mwendera C. <article-title update=\"added\"> Virtual care pathways for people living with <scp>HIV:<\/scp> A mixed\u2010methods systematic review. HIV Med. 2025;26(1):44\u201369. https:\/\/doi.org\/10.1111\/hiv.13701.","journal-title":"HIV Med"},{"issue":"7","key":"5039_CR44","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad341","volume":"10","author":"A Tarfa","year":"2023","unstructured":"Tarfa A, Sayles H, Bares SH, Havens JP, Fadul N. Acceptability, feasibility, and appropriateness of implementation of long-acting injectable antiretrovirals: a national survey of ryan white clinics in the United States. Open Forum Infect Dis. 2023;10(7):ofad341. https:\/\/doi.org\/10.1093\/ofid\/ofad341.","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"5039_CR45","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf192","volume":"12","author":"J Hack","year":"2025","unstructured":"Hack J, Tarfa A, Sayles H, Fadul N. High acceptability but persistent barriers to implementation of long-acting injectable antiretrovirals: a nationwide cross-sectional survey of ryan white clinics in the United States. Open Forum Infect Dis. 2025;12(4):ofaf192. https:\/\/doi.org\/10.1093\/ofid\/ofaf192.","journal-title":"Open Forum Infect Dis"},{"issue":"Suppl 4","key":"5039_CR46","doi-asserted-by":"publisher","first-page":"S541","DOI":"10.1093\/cid\/ciac716","volume":"75","author":"SE Cooper","year":"2022","unstructured":"Cooper SE, Rosenblatt J, Gulick RM. Barriers to uptake of long-acting antiretroviral products for treatment and prevention of human immunodeficiency virus (HIV) in high-income countries. Clin Infect Dis. 2022;75(Suppl 4):S541\u20138. https:\/\/doi.org\/10.1093\/cid\/ciac716.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"5039_CR47","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae087","volume":"11","author":"P Manghani","year":"2024","unstructured":"Manghani P, Monroe A, Castel A, et al. Low uptake of long-acting injectables in the first 2.5 years following approval among a cohort of people living with HIV. Open Forum Infect Dis. 2024;11(5):ofae087. https:\/\/doi.org\/10.1093\/ofid\/ofae087.","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"5039_CR48","doi-asserted-by":"publisher","DOI":"10.1093\/haschl\/qxaf016","volume":"3","author":"LC Zalla","year":"2025","unstructured":"Zalla LC, Horn T, Lujintanon S, Lesko CR. State-level variation in access to long-acting injectable antiretroviral therapy for HIV in the United States. Health Aff Sch. 2025;3(2):qxaf016. https:\/\/doi.org\/10.1093\/haschl\/qxaf016.","journal-title":"Health Aff Sch"},{"issue":"3","key":"5039_CR49","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/QAI.0000000000002337","volume":"84","author":"MM Philbin","year":"2020","unstructured":"Philbin MM, Parish CL, Kinnard EN, et al. Multisite study of women living with HIV\u2019s perceived barriers to, and interest in, long-acting injectable antiretroviral therapy. J Acquir Immune Defic Syndr. 2020;84(3):263\u201370. https:\/\/doi.org\/10.1097\/QAI.0000000000002337.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"9","key":"5039_CR50","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac455","volume":"9","author":"LF Collins","year":"2022","unstructured":"Collins LF, Corbin-Johnson D, Asrat M, et al. Early experience implementing long-acting injectable Cabotegravir\/Rilpivirine for human immunodeficiency virus-1 treatment at a ryan white-funded clinic in the US south. Open Forum Infect Dis. 2022;9(9):ofac455. https:\/\/doi.org\/10.1093\/ofid\/ofac455.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"5039_CR51","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1093\/cid\/ciae620","volume":"81","author":"SL Ford","year":"2025","unstructured":"Ford SL, Felizarta F, Han K, et al. Thigh injections of cabotegravir\u2009+\u2009rilpivirine in virally suppressed adults with HIV-1: a substudy of the phase 3b ATLAS-2M study. Clin Infect Dis. 2025;81(1):101\u201312. https:\/\/doi.org\/10.1093\/cid\/ciae620.","journal-title":"Clin Infect Dis"},{"issue":"10485","key":"5039_CR52","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(25)00405-2","volume":"405","author":"V Jogiraju","year":"2025","unstructured":"Jogiraju V, Pawar P, Yager J. Pharmacokinetics and safety of once-yearly lenacapavir: a phase 1, open-label study. Lancet. 2025;405(10485):1147\u201354. https:\/\/doi.org\/10.1016\/S0140-6736(25)00405-2.","journal-title":"Lancet"}],"container-title":["AIDS and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-026-05039-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10461-026-05039-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-026-05039-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T11:32:31Z","timestamp":1784892751000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10461-026-05039-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":52,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["5039"],"URL":"https:\/\/doi.org\/10.1007\/s10461-026-05039-z","relation":{},"ISSN":["1090-7165","1573-3254"],"issn-type":[{"value":"1090-7165","type":"print"},{"value":"1573-3254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"assertion":[{"value":"12 January 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}